Pfizer-J&J Alzheimer’s Drug Fails to Aid Cognition
Pfizer Inc. (PFE), Johnson & Johnson (JNJ) and Elan Corp. (ELN)’s experimental treatment for Alzheimer’s disease failed to show effectiveness in a late-stage clinical trial.
>
Intended to eliminate plaques in the brain that are a hallmark of the illness, bapineuzumab is in a race with a similar product being developed by Eli Lilly & Co. (LLY) to become the first broadly available drug designed to target a cause of Alzheimer’s, rather than just its symptoms.
“While we are disappointed in the topline results of Study 302, a more complete understanding of bapineuzumab and its potential utility in mild-to-moderate Alzheimer’s disease will be gained,” said Steven Romano, Pfizer’s head of medicine development for primary care, in the statement.
Patients in the study, dubbed 302, won’t keep taking the drug, New York-based Pfizer said, and three other bapineuzumab trials will continue as planned.
http://www.bloomberg.com/news/2012-07-23/pfizer-j-j-alzheimer-s-drug-fails-to-aid-cognition.html
